Akers Biosciences Share Discussion Threads

[wigwammer] 11/8/2016 15:35

I think even the good doctor would just concede to losses on this one.Let's keep it simple then:"When will we hear about networks adopting pifa hep?""Difficult to forecast precisely.. but before the end of the year".Sound about right?

[mcmather] 11/8/2016 15:05

Keep it simple and take it as what he said; ie "difficult to forecast".

The good doctor would have said he hit out of the park, into blue sky, a game changer of a buy / sell...

[wigwammer] 11/8/2016 15:01

"Just some timely / lucky trading along the way.."Did Ray Akers write this?

[wigwammer] 11/8/2016 15:00

I'll take that as a yes.

[mcmather] 11/8/2016 14:55

And/or he said that it was difficult to forecast.

[wigwammer] 11/8/2016 14:52

Gormally stated announcements re hospital network adoption and pifa hit are likely before year end, didn't he?

[mcmather] 11/8/2016 14:43

Costs have been reigned in, Wally sideswiped with some prospects but still think the US sales of the flagship PIFA product will be the key for the next 12 months; if the US hospitals don't take it up then I can't see too many other countries doing so.

The oxidative range of tests should make an "attractive contribution towards our performance in H2"...

[mcmather] 11/8/2016 14:38

References to a figure around $7m/$7.5m should attain a cash positive status. However, whilst Wally was dithering when asked about future financing (ie placings) he then pulled his rabbit out of his hat (fortunately a verbal call only without pictures!) and mentioned that the company WAS cash positive for the first time in June 2016; so presumably revenues around / in excess of $0.625m which I presume will be the two tranches of payment from Novotek?

[mcmather] 11/8/2016 14:32

ww, appreciate they implemented the new strategy earlier in the year but that still does not account for why US sales of PIFA Heparin fell by 40% in Q2; baldly, 40% of those who bought the device in Q1, for whatever reason - including the company now targeting regional health care providers as opposed to stand alone hospitals - did not do so to the same effect in Q2.

[mcmather] 11/8/2016 14:02

Conference call imminent but nasdaq pre-opening looks interesting.

[mcmather] 11/8/2016 09:44

Agree Norbus.

[mcmather] 11/8/2016 09:42

ww, I'll have another look later but the notes I reviewed last night included Gormally advising (in resect of the flagship product) that growth rates will continue to improve in 2016 hence the post above. Tightening up on matters that Dr Walt oversaw would not, I imagine, have been too difficult.

[norbus] 11/8/2016 09:24

mcm

you can see the tidying up of numbers for a placing; survival depends on the new man doing M&A Their products have been around far too long not to be discovered.

[mcmather] 11/8/2016 09:10

And about bleeding time; Wally has been rewarding himself extravagantly here for far too long despite continual woeful performance in terms of results and shareholder value.

"The increase in personnel costs for the six months ended June 30, 2016 is the result of increases in costs associated with employee benefits and the addition of a staff accountant in June 2015 and the Company's new Chief Executive Officer in November 2015. These increases were offset by the transfer of Dr. Akers to the Research and Development Department effective April 25, 2016".

[wigwammer] 11/8/2016 09:07

"There is a still a massive amount of bluster from the management team."Perhaps. Or perhaps there are reasonable reasons why US volumes were front loaded into q1. Conf call may shed light on this.Taking the weaker quarter, annualising it, ignoring the china order, ignoring the drop in cash consumption, ignoring the guidance of the new chief exec etc.. may also be taken as bluster.

[mcmather] 11/8/2016 08:39

There is a still a massive amount of bluster from the management team and concerns re the credibility of the company's flagship PIFA Heparin/PF4 Rapid Assay products in their base in the US:

Q1 Highlights

- Product Revenue for Q1 was $738,023.

- Flagship PIFA Heparin/PF4 Rapid Assay products driving growth, with $635,173 worth of sales in Q1 almost entirely to US hospitals......It is encouraging to note that this sales growth is currently expressed mainly in the increase in the price of the products.

H1 Financial Highlights:

- Product revenue up 47% for H1 2016 to $1,694,510.

- Sales of flagship PIFA Heparin/PF4 Rapid Assay products up 68% to $1,514,255.

- Experiencing strong growth from flagship PIFA Heparin/PF4 Rapid Assay product sales boosted by sales to China ($2,500,000 order from Novotek for 2016 of which $505,380 shipped in H1 and balance due in tranches through H2).

$505,380 from $1,514,255 = $1,008,875 minus applicable sales from Q1 of $635,173 = $373,702; ie a drop in sales of the flagship product in their own country of over 41% in Q2 from Q1...

$373,702 equates to just shy of $1.5m per annum which is only marginally better than the company has attained over the past 8 years or so and this including a big hike in the price.

Hmmm.

[wigwammer] 11/8/2016 08:05

Q1 cash burn $1.8m.Q2 cash burn $0.7m."The Company has turned a corner and the combined effect of improved sales and reduced costs is accelerating the path to profitability - a goal which we believe is now coming firmly into view."

[this_is_me] 11/8/2016 07:57

H2 results look promising. Placing after final results?

[mcmather] 10/8/2016 23:27

Half yearly's tomorrow am. Losses need to have reduced otherwise a placing - which will probably happen anyway - seems inevitable.

[rivaldo] 04/8/2016 07:22

Closed nicely up in the USA last night at the equivalent of 240p, so hopefully the UK will catch up today.

[mcmather] 01/8/2016 22:47

Bit of speculation on AKER (nasdaq); "..... is expected to rise 74.8% during the next 3 months..."
'Buy' Friday, 'Sell today:

[rivaldo] 01/8/2016 13:06

A 2,500 share buy at 223p today out of the blue, and a tick up.

Woke me up :o))

[mcmather] 26/7/2016 08:27

Just some timely / lucky trading along the way - the obvious potential here and in the area that AKR operate has unfortunately always been tempered by Wally's unusual ways.

[wigwammer] 25/7/2016 07:26

ie you sold a lot of your shares?!

[mcmather] 22/7/2016 15:59

Good old Wally norbus! Fortunately got myself in a position here were a complete failure had been mostly protected.